4th International Conference on
Cancer Research
Scientific Program
Christine Boers-Doets
Cancer-Med, The Netherlands
Title: Effective approach to adverse events of cancer medication: Utopia or Reality?
Biography:
She has 20 years’ experience in mentoring and training scientific and clinical professionals working within cancer drug development and application. She has mentored over 21 pharmaceutical companies globally; as well as this, she has trained healthcare providers with her online coaching, live events, books and videos to achieve the Adverse Event Expert title. COSTA, CancerMed’s Online Stakeholder Tailored Adverse Event Expert Intensive, is her interdisciplinary online signature course.
Abstract
Targeted cancer therapies are increasingly used in oncology care as single agents or in combination with other classes of oncology care. Like other treatment options, targeted therapies are associated with adverse events which may cause treatment adjustments and deterioration of quality of life. Targeted therapies may induce adverse event burden, with or without significant clinical evidence of tissue damage, while having far reaching consequences for patient adherence with care and therefore cancer treatment outcomes. To be able to complete treatment as planned and to maintain quality of life, adverse events need to be addressed according to the patient’s needs. Therefore, the patient’s view is a critical component of an integral approach to adverse events of targeted agents.
For the best treatment outcomes, you will need to solve the challenges that patients encounter when on targeted anticancer treatment. One of these challenges are the occurrence of adverse events. The level of adverse event expertise you personally need depends on the level of expertise the other team members are on and the clinical trials you are involved. In all cases, initiation of the most appropriate adverse event treatment is more likely to occur if the adverse events are addressed with the 6-step practical approach. Running an effective patient consultation requests special habits. The institution of adverse event subtypes is one of those habits. The ASK method is another success habit. In this lecture I will guide you through the options to consider so all involved parties will benefit.
- Organ Defined Cancers
- Pediatric Oncology
- Oncology Nursing
- Cancer Metastasis
- Cancer Biomarkers
- Precision Cancer Medicine
- Cancer Bio-Informatics
- Chemotherapy
- Imaging and Radiation Therapy
- Cancer and Stem Cell Therapy
- Neuro-Oncology
- Cancer Awareness and Survival
Christine Boers-Doets
Cancer-Med, The Netherlands
Title: Effective approach to adverse events of cancer medication: Utopia or Reality?
Biography:
She has 20 years’ experience in mentoring and training scientific and clinical professionals working within cancer drug development and application. She has mentored over 21 pharmaceutical companies globally; as well as this, she has trained healthcare providers with her online coaching, live events, books and videos to achieve the Adverse Event Expert title. COSTA, CancerMed’s Online Stakeholder Tailored Adverse Event Expert Intensive, is her interdisciplinary online signature course.
Abstract
Targeted cancer therapies are increasingly used in oncology care as single agents or in combination with other classes of oncology care. Like other treatment options, targeted therapies are associated with adverse events which may cause treatment adjustments and deterioration of quality of life. Targeted therapies may induce adverse event burden, with or without significant clinical evidence of tissue damage, while having far reaching consequences for patient adherence with care and therefore cancer treatment outcomes. To be able to complete treatment as planned and to maintain quality of life, adverse events need to be addressed according to the patient’s needs. Therefore, the patient’s view is a critical component of an integral approach to adverse events of targeted agents.
For the best treatment outcomes, you will need to solve the challenges that patients encounter when on targeted anticancer treatment. One of these challenges are the occurrence of adverse events. The level of adverse event expertise you personally need depends on the level of expertise the other team members are on and the clinical trials you are involved. In all cases, initiation of the most appropriate adverse event treatment is more likely to occur if the adverse events are addressed with the 6-step practical approach. Running an effective patient consultation requests special habits. The institution of adverse event subtypes is one of those habits. The ASK method is another success habit. In this lecture I will guide you through the options to consider so all involved parties will benefit.
- Organ Defined Cancers
- Pediatric Oncology
- Oncology Nursing
- Cancer Metastasis
- Cancer Biomarkers
- Precision Cancer Medicine
- Cancer Bio-Informatics
- Chemotherapy
- Imaging and Radiation Therapy
- Cancer and Stem Cell Therapy
- Neuro-Oncology
- Cancer Awareness and Survival
